1
AstraZeneca LP, Wilmington, DE, USA, 2 Strategic Healthcare Solutions, LLC, Monkton, MD, USA OBJECTIVES: Individuals with type 2 diabetes mellitus (T2DM) utilize more health care resources than those without diabetes, yet a portion of the increased use may be due to comorbid conditions. This study compared health care resource utilization among adults with T2DM plus hypertension (HTN) and obesity with those with T2DM only. METHODS: Respondents to the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD), a large US survey, self-reported their height, weight, comorbid conditions, number of hospitalizations, emergency department (ED) visits, and physician visits in the past 12 months. Respondents reporting T2DM and HTN and obesity (body mass index [BMI] ≥30 kg/m 2 ) were identified and compared with a T2DM-only group. RESULTS: T2DM respondents with, comorbid HTN, and obesity (n = 1186), were younger, more likely to be men, and had lower income but were similar to T2DM-only respondents (n = 293) in race, education, smoking, and cardiovascular disease history. Respondents with T2DM, HTN, and obesity had significantly more physician visits (mean of 8 vs. 6, p = 0.001), especially 10 or more visits (21% vs. 15%), than respondents with T2DM only (p = 0.03). No significant differences (p > 0.05) were reported for percentage hospitalized (21% vs. 20%) and number of days hospitalized (mean of 7 vs. 11 days) over the past 12 months. Respondents with comorbid HTN and obesity reported significantly more ED visits (9% with 2-13 visits) compared with T2DM-only group (5% with 2-5 visits, p = 0.02). CONCLUSIONS: Respondents with comorbid conditions of T2DM, HTN, and obesity have greater health care resource utilization in physician office visits and ED visits than those with T2DM only.
PCV92 ARE DOUBLE-BLIND, DOUBLE-DUMMY STUDIES SUITABLE FOR RESOURCE UTILISATION ANALYSES? AN EXAMPLE FROM A NEW ORAL ANTICOAGULANT FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) FOLLOWING ORTHOPAEDIC SURGERY
Roskell N 1 , Wolowacz S 1 , Christiansen AV 2 , Plumb JM 3 1 RTI Health Solutions, Manchester, UK, 2 Boehringer Ingelheim Danmark A/S, Copenhagen OE, Denmark, 3 Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany OBJECTIVES: Resource utilisation data were collected in all three Dabigatran etexilate (DBG) Phase III primary VTE prevention following orthopaedic surgery studies. This study aimed to, within trial, summarise resource use by treatment group and compare resource use separately for each dose of orally-administered DBG (150 mg od, 220 mg od) versus subcutaneous enoxaparin. METHODS: The RE-MOBILIZE study included 2596 knee-surgery patients and compared DBG to enoxaparin 30 mg bid. The RE-MODEL and RE-NOVATE studies included 2076 and 3463 patients undergoing knee and hip surgery respectively, and compared DBG with enoxaparin 40 mg od. All studies used a randomised, double-blind, double-dummy non-inferiority design. Duration of treatment differed by study. Data collected for all patients included hospitalisation (main and re-admission), non-protocoled diagnostics, blood transfusions, reoperations, concomitant medications and health care contacts for enoxaparin injections. Each resource use category was summarised, separately for each study, by and between treatment using means and standard errors. Two sample t-tests were used to examine differences between treatments. RESULTS: There were no consistently significant differences between treatments (within each study). The percentages of patients requiring domiciliary nurse visits to administer thromboprophylaxis following discharge from hospital (i.e. administer subcutaneous enoxaparin or placebo because the patient was unable to self-inject) were 5.6% (DBG 150 mg od), 5.0% (DBG 220 mg od) and 5.4% (enoxaparin) in RE-MOBILIZE, 1.0%, 1.5% and 1.9% in RE-MODEL, and 4.4%, 5.1% and 5.0% in RE-NOVATE. All domiciliary nurse visit comparisons for each DBG arm versus enoxaparin were statistically non-significant (P > 0.15). CONCLUSIONS: Double-blind, double-dummy study designs appear to be unhelpful in the identification of differences that might arise from changes in treatment formulation and route of administration. In this study, a hypothesised difference in domiciliary nurse treatment administrations remained undetected due to the doubledummy nature of the trials.
PCV93 DISCRETE EVENT SIMULATION OF CARDIAC HOSPITALS PERFORMING PERCUTANEOUS CORONARY INTERVENTIONS
Pei P 1 , Kongnakorn T 2 , Hernández L 3 , Bae JP 4 , Ramaswamy K 5 , Moller J 6 1 United Biosource, Lexington, MA, USA, 2 United Biosource Corporation, Lexington, MA, USA, 3 United BioSource Corporation, Bogotá, Colombia; Universidad de los Andes, Bogotá, Colombia, 4 Eli Lilly and Company, Indianapolis, IN, USA, 5 Daiichi Sankyo, Inc., Parsippany, NJ, USA, 6 United BioSource Corporation, Eslov, Sweden OBJECTIVES: Efficient facility operation is an important factor in quality of care for hospitals. How treatment protocols influences efficiency and productivity of a cardiac hospital is little known. METHODS: A discrete event simulation model of a cardiac hospital with percutaneous coronary intervention (PCI) capability was built on analysis of time-stamped electronic medical record database (Cerner Health Facts®). Additional data were obtained from PCI literature, TRITON TIMI-38 trial, hospital statistics, and expert opinions. ACS treatment options include PCI, coronary arterial bypass graft (CABG), or drug therapy. Three oral antiplatelet dosing strategies for unstable angina (UA) and non-ST segment myocardial infarction (NSTEMI) were considered with loading dose given at PCI, minimum 2 hours prior, and minimum 6 hours prior to PCI. Facility occupancy, wait, PCI volume, and length of stay, were tracked. RESULTS: Pre-treatment strategy increased patients' total time in the hospital for all ACS-PCI, with an average time of 114.96 hours with loading dose at PCI, 118.32 hours (+2.92%) with minimum 2 hours prior, and 121.68 hours (+5.85%) with minimum 6 hours prior. For UA/NSTEMI subgroup, total time in hospital was 129.04 hours with loading at PCI, 134.51 hours (+4.24%) with minimum 2 hours prior, and 140.38 hours (+8.79%) with minimum 6 hours prior to PCI. Increase was mainly in pre-procedure time. Pre-treatment has no significant effect on procedure times. Among the CABG-bound patients, pre-operation times increased by 33.49 hours (+85.77%) and 35.47 hours (+90.83%) under 2 and 6 hour pre-treatment strategy, respectively. CONCLUSIONS: Pretreatment strategy with oral antiplatelet is likely to cause some inefficiency in hospital due to waits and longer total stay. This may increase facility congestion, occupancy, and staff hours. In CABG-bound patients, pretreatment leads to additional days due to recommended wait. The pretreatment strategy as a way to optimize antiplatelet therapy in ACS-PCI entails efficiency costs.
CARDIOVASCULAR DISORDERS -Patient-Reported Outcomes Studies

PCV94 CONCORDANCE AMONG THREE SELF-REPORTED MEASURES OF MEDICATION ADHERENCE AND COUNT OF TABLETS RECORDS IN COLOMBIAN HYPERTENSIVE PATIENTS
Garcia Vega OA, Buendia Rodriguez JA Universidad Nacional de Colombia, Bogota, Colombia OBJECTIVES: To evaluate the level of agreement among three previously validated self-reported medication adherence measures and count of tablets records METHODS: This was a cross-sectional study which included adult patients (40 and older) with hypertension disease enrolled continuously for 6 months in a private medical center. Random sequences of tests (communication of self-compliance (SC), Morinsky-Green Test (MG) and knowledge of the illness (KI)) were used to estimate the adherence of antihypertensive medication. Threshold of 80% was used to determine adherence with count of tablets. Concordances were assessed using Cohen's kappa coefficient (k) and prevalence-adjusted bias-adjusted kappa (PABAK). RESULTS: A total of 151 hypertensive patients were included in the study. A total of 65.5% of these patients have other comorbilities and 45.6% took more than 5 drugs per day. The prevalence of non adherence, using a tablet count as reference test, was 8%. Due substantial imbalance in the fourfold table's marginal totals we found high agreement of negative results (SC (0, 94), MG (0.60), KI (0.72)) but low Kappa (SC (k:-0,03), MG (k: 0,06), KI (k:−0,01)).The Kappa values adjusted (PABAK) were SC (k:0.79), MG (k: −0,06), KI (k:0,15). CONCLUSIONS: Because of the weak to moderate concordance found among validated measures of adherence, the selection of a useful adherence measure in clinical practice is difficult. These findings underscore the difficulty in both assessing patients' medication-taking behavior and assessing and comparing the results of adherence research. The development of valid and reliable measures for easily assessing medication adherence behavior in clinical setting is needed.
PCV95 PREDICTIVE MODELS TO IDENTIFY NON-ADHERENCE TO DYSLIPIDEMIC MEDICATIONS USING PHARMACY AND MEDICAL CLAIMS DATA FROM A COMMERCIAL HEALTH PLAN
Wiegand P 1 , McCombs J 2 , White J 3 , Wang JJ 4 1 University of Southern California, Venice, CA, USA, 2 USC School of Pharmacy, Los Angeles, CA, USA, 3 WellPoint NextRx, West Hills, CA, USA, 4 Clinical Analyst / WellPoint, Inc., Thousand Oaks, CA, USA OBJECTIVES: To develop predictive models for medication compliance in dyslipidemia that will aid health care decision makers in targeting compliance intervention programs. METHODS: Pharmacy and medical claims data from a commercial health plan were analyzed for all currently enrolled members who received their first dyslipidemic medication between May 1, 2007 and April 30, 2008. Percentage of days covered (PDC) defined as days supply of dyslipidemic medication per 365 days. PDC < 80% was used to categorize non-compliant patients. Potential independent variables included patient demographics, pharmacy utilization and medical conditions. Stepwise logistic regression was used to predict the odds of non-compliance. RESULTS: A total of 88,635 patients were included. Sixty-five percent of patients were non-compliant (PDC = 0.33; SD = 0.22). The most significant predictor of non-compliance was treatment with bile acid sequestrants (OR: 6.75; p < 0.0001, compared to statins). Significant predictors of non-compliance also included age category, increasing from an OR = 1.11 for age 45-55 to OR = 3.23 for age <18 [p < 0.0001 for all estimates compared to age 75+]; prior diabetes diagnosis (OR: 1.15, p < 0.0001) and the number of unique pharmacies used (OR = 1.10 per additional pharmacy; p < 0.0001). Factors reducing non-compliance include male gender (OR: 0.77, p < 0.0001); previous heart attack (OR: 0.82; p = 0.0221); prior compliant behavior (OR: 0.888; p < 0.0001); number of unique physicians seen for medications (OR: 0.969 per additional physician; p < 0.0001) and copayment categories (relative to no copayment). Compliance significantly improved by 12%, 12% and 6% for copay categories $5-$10, $10-$20, and $20-$30, respectively to no copayment. (p < 0.01). CONCLUSIONS: The results may be used by health care decision makers to identify patients who are most likely to be non-compliant with dyslipidemia therapy and help focus medication compliance efforts. A secondary analysis using corresponding lab data is projected. Linear mixed model analysis showed that patient's MPR increased by 3.66% when patients were enrolled under Medicare. Patients were persistent to their drug therapy for an average of 151.76 days under Medicaid and days of persistence increased to 159.75 days during the Medicare period. Linear mixed model analysis showed that patients were persistent for 7.99 extra days after they were enrolled in Medicare Part D. Average number of gap days in therapy during the Medicaid period was 11.91 days and decreased to 8.38 days during the Medicare period. Linear mixed model analysis showed that average number of gap days in therapy decreased by 3.52 days when patients were enrolled in Medicare Part D. Linear mixed model analysis and linear regression analysis showed that as patient out-of-pocket costs increased, patient medication possession ratio and persistence increased and average number of gap days in therapy decreased. CONCLUSIONS: These results suggest that dual-eligible beneficiary's medication utilization increased after implementation of Medicare Part D. Based on these results it can be concluded that higher out-of-pocket costs for dualeligible beneficiaries under Medicare Part D did not have a negative impact on their drug adherence and persistence.
PCV96
IMPACT OF MEDICARE PART D ON ADHERENCE AND PERSISTENCE WITH STATIN MEDICATIONS FOR TEXAS DUAL-ELIGIBLE BENEFICIARIES
PCV97 ANALYSIS ON THE EFFECTS OF MEDICARE PART D COVERAGE GAP ON STATIN MEDICATION ADHERENCE
Pai J 1 , Zeng F 2 , Patel BV 2 , Sanchez RJ 3 , McCombs J 1 1 USC School of Pharmacy, Los Angeles, CA, USA, 2 MedImpact Healthcare Systems, San Diego, CA, USA, 3 Pfizer Inc., New York, NY, USA OBJECTIVES: To investigate the impact of the coverage gap in the Medicare Part D program on statin medication adherence. METHODS: A pharmacy claims database from a national pharmacy benefit management company was used for this retrospective analysis. The sample includes Medicare Part D patients 65 years and older who 1) used statins in both 2007 and 2008, and 2) entered the coverage gap (donut hole), but did not reach the catastrophic phase in 2008. Adherence was measured by a dummy variable indicating whether the proportion of days covered was greater than or equal to 0.8. A difference-in-differences regression analysis was used to evaluate the effect of the coverage gap by comparing adherence to statins before and after the start of the donut hole. RESULTS: A total of 26,686 patients were identified. Beneficiaries were mostly women (55.5%) with an average age of 75 years. Patients in the study were divided into three groups based on level of coverage in the donut hole: no coverage (N = 4,984), generic drug coverage (N = 6,063), or generic and brand drug coverage (N = 15,639). After patients entered the donut hole, the average 30-day co-payment for statin medications increased notably for beneficiaries who had no drug coverage ($21.62 to $49.72) or generic only coverage ($22.22 to $42.04), but decreased for those with generic and brand drug coverage ($20.12 to $16.63) Compared to beneficiaries with both generic and brand medication coverage, beneficiaries with no coverage (OR = 0.581, p < 0.0001, 95% CI 0.525-0.645) and beneficiaries with only generic medication coverage (OR = 0.662, p < 0.0001, 95% CI 0.601-0.728) were less likely to be adherent to statin medications after entering the donut hole. CONCLUSIONS: Medicare beneficiaries with no coverage or generic only coverage were less likely than those with a more comprehensive gap coverage to be adherent to statins after entering the donut hole.
PCV98 ADHERENCE TO LIPID LOWERING THERAPIES AS A PREDICTOR OF CHOLESTEROL OUTCOMES: A LITERATURE REVIEW
Uzoigwe C 1 , Tunceli K 1 , Hu X( 2 1 Merck, Whitehouse Station, NJ, USA, 2 Merck, West Point, PA, USA OBJECTIVES: Despite the benefits of lipid lowering therapies (LLT), adherence to LLT remains poor. This review aims to summarize and assess evidence from prior research on the association between adherence to LLT and cholesterol outcomes (cholesterol levels and/or goal attainment). METHODS: We searched PubMed database for research articles written in English and published between January 1, 2000 and December 31, 2009 using combinations of the following terms: "adherence," "compliance," "statin," and "lipid lowering". Retrieved articles were included for review if they met the criterion of adherence/compliance as a predictor of cholesterol outcomes (e.g., LDL-C, HDL-C, or TC). RESULTS: The automated literature search yielded 527 studies, 8 of which met the inclusion criteria. Despite that a majority of studies examined adherence to LLT, only a few included cholesterol outcomes. A total of 519 studies were excluded: 340 for being off topic, 5 for having no adherence measure, and 174 for having no cholesterol measures reported as an outcome. This review initially sought to quantify the effect of adherence on cholesterol outcomes; however, adherence measures and methods varied greatly among the 8 studies and made data synthesis challenging. Heterogeneous methodologies were used for adherence measures, including medication possession ratio (MPR), medication event monitoring system (MEMS), adherence to therapy index (ATI), continuous measure of medication gaps (CMG) and pill counting. Regardless of how adherence was defined, better adherence was associated with improved cholesterol outcomes (lower LDL-C or TC or higher HDL-C levels compared to their respective baseline levels). CONCLU-SIONS: Few studies evaluated both adherence to LLT and cholesterol outcomes and various methodologies were used for adherence measurements. Further studies assessing compliance and objective clinical endpoints are needed. Health care providers should monitor medication adherence and develop effective interventions to improve adherence given the evidence on improved cholesterol outcomes as a result of increased adherence.
PCV99 THE ROLE OF ILLNESS BURDEN AND MEDICATION BELIEFS IN MEDICATION COMPLIANCE OF ELDERLY WITH HYPERTENSION
Rajpura JR, Nayak R St.John's University, Jamaica, NY, USA OBJECTIVES: To measure the impact of illness burden and medication beliefs on medication compliance of elderly with hypertension using a tool that pictorially represents the burden of illness on self. METHODS: A cross-sectional research design, utilizing convenience sampling strategies and self-administered surveys of elderly hypertensive residents living in New York City senior care centers. Medication compliance was measured using Morisky's test, medication beliefs were measured using beliefs about medication questionnaire (BMQ), and illness burden was operationalized by implementing Pictorial Representation of Illness and Self Measure-Revised II (PRISM-RII) instrument. PRISM is a novel and visual measurement tool of suffering that consists of two components, namely, self illness separation (SIS) and illness perception measure (IPM).Additionally, two index scores, namely World Health Organization (WHO-5) wellbeing score and Suffering Question (SQ) scores were also computed to further examine interrelationships among study variables. RESULTS: About 33% of the 120 hypertensive elderly cohorts who responded to the survey were found to be noncompliant with their blood pressure medications. Morisky's score correlated significantly and positively with both BMQ differential scores (r = −0.303, p = 0.001) and SIS component scores (r = −0.425, p = 0.000) respectively. General Overuse (GO) scores and IPM component scores correlated positively with Morisky's score (r = 0.347 & 0.440, p = 0.000). SIS correlated positively with WHO-5 (r = 0.142, p = 0.126) and negatively with IPM (r = −0.841, p = 0.000). CONCLUSIONS: Beliefs about the benefits of taking medications outweigh the costs and risks of taking them. Higher perceived illness burden in hypertension translates into lower medication compliance in elderly. PRISM-RII may be a useful measure of illness burden in compliance research in elderly populations. The study underscores the importance of incorporating patient perceptions about medications and illness burden into decisions involving hypertension management.
PCV100
INTERVENTIONS TO IMPROVE COMPLIANCE WITH LIPID LOWERING MEDICATIONS: A SYSTEMATIC REVIEW OF THE LITERATURE
Zuluaga A 1 , Salas M 2 , Gwadry-Sridhar F 3 , Manias E 4 , Hughes D 5 1 University of Alabama at Birmingham, Birmingham, AL, USA, 2 AstraZeneca, LP, Wilmington, DE, USA, 3 University of Western Ontario, Ontario, ON, Canada, 4 Melbourne School of Health Sciences, Carlton, Victoria, Australia, 5 Bangor University, Bangor, UK OBJECTIVES: To identify the most effective interventions to improve patient compliance with lipid lowering medications. METHODS: A systematic review was conducted using Medline, Cumulative Index to Nursing and Allied Health Literature, EMBASE, Cochrane Library, and references of review articles, and meta-analyses. Abstracts of studies published between 1999 and 2009, irrespective of language that included the terms: hyperlipidemia, hypercholesterolemia, lipid lowering medications and adherence, compliance, and interventions were screened. Studies with incomplete information, lack of adherence measure, overviews and letters to editors were excluded. Full articles of studies on interventions that reported the use of a comparator group and reported quantitative data on compliance were included. Two independent researchers reviewed papers, and disagreements were agreed by consensus. A standardized data extraction form was used to record details on study design, objectives, randomization, blinding, comparator group, type of intervention, outcomes, population, follow up, ethics approval, sample size, statistical analysis and results. A quality score was calculated using the Downs modified scale. RESULTS: Of 130 titles, 79 abstracts were screened and only 15 studies fulfilled the inclusion criteria. Study heterogeneity precluded a quantitative meta-analysis. Most interventions improved drug compliance from 15% for single interventions to 27% for complex interventions. Most studies focused on pharmacist-led interventions, and the most effective included the use of telephone reminders, card reminders, brochures, and booklets. All interventions were able to reduce LDL and/or total cholesterol. Average index quality score was 40%. CONCLUSIONS: Interventions focused on improving compliance reduce LDL and total cholesterol. The most effective interventions to improve compliance with lipid lowering medications are complex, multi-factorial interventions. However, reports have variable quality.
